Trial Profile
A Phase 2, 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients With Acute Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms STEP 203
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 12 Jan 2011 Status of parent trial changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2010 Status of parent trial changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India).